Traders purchased shares of C.R. Bard Inc. (NYSE:BCR) on weakness during trading hours on Thursday after an insider sold shares in the company. $63.09 million flowed into the stock on the tick-up and $29.26 million flowed out of the stock on the tick-down, for a money net flow of $33.83 million into the stock. Of all equities tracked, C.R. Bard had the 18th highest net in-flow for the day. C.R. Bard traded down ($3.56) for the day and closed at $223.74Specifically, Chairman Timothy M. Ring sold 110,000 shares of the business’s stock in a transaction dated Monday, September 26th. The stock was sold at an average price of $228.96, for a total value of $25,185,600.00. Following the sale, the chairman now directly owns 96,030 shares in the company, valued at $21,987,028.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Betty D. Larson sold 4,032 shares of the business’s stock in a transaction dated Monday, September 19th. The stock was sold at an average price of $225.33, for a total value of $908,530.56. Following the completion of the sale, the vice president now owns 10,298 shares in the company, valued at $2,320,448.34. The disclosure for this sale can be found here. 0.97% of the stock is owned by corporate insiders.
BCR has been the topic of several analyst reports. Wells Fargo & Co. raised C.R. Bard from a “market perform” rating to an “outperform” rating in a research note on Friday, September 16th. Leerink Swann reissued a “market perform” rating and set a $233.00 price objective (down from $240.00) on shares of C.R. Bard in a research note on Thursday, July 28th. Barclays PLC boosted their price objective on C.R. Bard from $224.00 to $235.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 27th. Zacks Investment Research cut C.R. Bard from a “buy” rating to a “hold” rating in a research note on Thursday, August 4th. Finally, Morgan Stanley reissued a “hold” rating and set a $240.00 price objective on shares of C.R. Bard in a research note on Thursday, July 28th. Thirteen analysts have rated the stock with a hold rating and six have given a buy rating to the company. C.R. Bard presently has a consensus rating of “Hold” and an average target price of $233.00.
The firm has a 50 day moving average price of $221.43 and a 200-day moving average price of $218.92. The company has a market capitalization of $16.43 billion, a P/E ratio of 52.03 and a beta of 0.57.
C.R. Bard (NYSE:BCR) last announced its earnings results on Tuesday, July 26th. The company reported $2.54 EPS for the quarter, beating analysts’ consensus estimates of $2.47 by $0.07. C.R. Bard had a net margin of 9.20% and a return on equity of 48.43%. The business earned $931.50 million during the quarter, compared to analysts’ expectations of $915.22 million. During the same period in the prior year, the company earned $2.27 earnings per share. The business’s revenue was up 8.3% compared to the same quarter last year. Equities research analysts forecast that C.R. Bard Inc. will post $10.17 EPS for the current year.
Large investors have recently made changes to their positions in the stock. NN Investment Partners Holdings N.V. acquired a new stake in shares of C.R. Bard during the first quarter worth approximately $100,000. Acrospire Investment Management LLC acquired a new stake in shares of C.R. Bard during the first quarter worth approximately $101,000. Northwestern Mutual Wealth Management Co. boosted its stake in shares of C.R. Bard by 415.1% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the company’s stock worth $104,000 after buying an additional 357 shares during the last quarter. Whittier Trust Co. of Nevada Inc. boosted its stake in shares of C.R. Bard by 43.7% in the second quarter. Whittier Trust Co. of Nevada Inc. now owns 454 shares of the company’s stock worth $107,000 after buying an additional 138 shares during the last quarter. Finally, LSV Asset Management acquired a new stake in shares of C.R. Bard during the second quarter worth approximately $123,000. 87.90% of the stock is owned by institutional investors and hedge funds.
About C.R. Bard
C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.